Rajnish Dhediya

ORCID: 0000-0002-6423-7993
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Diabetes Management and Research
  • Diabetes Treatment and Management
  • Diabetes Management and Education
  • Chronic Disease Management Strategies
  • Pancreatic function and diabetes
  • Heart Failure Treatment and Management
  • Pharmacology and Obesity Treatment
  • Mobile Health and mHealth Applications
  • Cardiovascular Effects of Exercise
  • Potassium and Related Disorders
  • Amino Acid Enzymes and Metabolism
  • Genetics and Neurodevelopmental Disorders
  • Acute Ischemic Stroke Management
  • Cardiac Structural Anomalies and Repair
  • Metabolism, Diabetes, and Cancer
  • Cardiomyopathy and Myosin Studies
  • Pharmacological Effects and Toxicity Studies

Dr. Reddy's Laboratories (India)
2021-2025

Emcure Pharmaceuticals (India)
2019-2021

King Edward Memorial Hospital and Seth G.S. Medical College
2016

Background: The purpose of this study was to evaluate the psychosocial status patients with type 2 diabetes (T2D) and treating physicians using a novel Glycemic Happiness (GH) scale. Methods: This real-world, prospective, multicentric, cross-sectional observational study. Male female participants aged ≥ 18 years clinical diagnosis T2D were eligible take part. Additionally, extensive patient experience enrolled in Results: included total 400 27 physicians. population consisted 213 (53.3%) men...

10.7759/cureus.80209 article EN Cureus 2025-03-07

Real-world Indian studies evaluating effectiveness of dapagliflozin as an add-on to other oral antidiabetic drugs (OAD) in patients with type 2 diabetes mellitus (DM) are scarce. An electronic medical record (EMR)-based, retrospective, multicentre study was conducted evaluate the therapy adult inadequately controlled DM on metformin or without OAD. Baseline characteristics (visit 1: plus OAD treatment for at least 30 days) and treatment-related outcomes 2: follow-up) considered between 60...

10.1007/s40801-023-00398-8 article EN cc-by-nc Drugs - Real World Outcomes 2023-10-28

Background: Tenecteplase, a third generation tissue plasminogen activator has important place in the thrombolytic therapy acute ischemic stroke. The objective of present study was to understand knowledge, attitude and practice (KAP) towards usage tenecteplase daily clinical practice.Methods: This prospective questionnaire based survey with involvement practising neurologists across country. A specially designed validated containing 18 questions shared their anonymous inputs were captured...

10.18203/2320-6012.ijrms20210485 article EN International Journal of Research in Medical Sciences 2021-02-09

Objective: Cardiomyopathy is defined as a heterogeneous group of diseases the myocardium, transient reversible, but potentially life-threatening condition. The natural history, management pattern, and outcome cardiomyopathy are not clear in Indian scenario. This study was conducted to investigate clinical features, prognostic predictors, outcomes patients with cardiomyopathy. Materials Methods: We retrospectively analyzed data 119 admitted tertiary care hospital from January 2016 April 2019....

10.4103/heartindia.heartindia_42_20 article EN cc-by-nc-sa Heart India 2021-01-01

Background: Teneligliptin is a DPP-4 inhibitor with unique chemical structure. Efficacy and safety of well established in the patients type 2 diabetes mellitus (T2DM) different randomized controlled trials. However, limited real-world data available for pertaining to Indian T2DM patient profile such as demographics, duration disease, currently prescribed anti-hyperglycemic drugs, initiation monotherapy or an add on therapy.Methods: A cross-sectional, multicenter, non-interventional study was...

10.18203/2319-2003.ijbcp20192648 article EN International Journal of Basic & Clinical Pharmacology 2019-06-24
Coming Soon ...